Related Experiment Videos
Rad23 as a reciprocal agent for stimulating or repressing immune responses
Helen A Andersson1, Marco F Passeri, Michael A Barry
1Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital, and Texas Children's Hospital, Houston, TX 77030, USA.
Human Gene Therapy
|May 27, 2005
Summary
Rad23 protein enhances proteasome degradation of antigens, boosting CD8+ T-cell responses for vaccines. It can also inhibit degradation to dampen immune responses, useful for gene therapy.
Area of Science:
- Immunology
- Molecular Biology
- Protein Degradation
Background:
- The proteasome degrades cellular proteins, presenting peptides via MHC class I for CD8+ T-cell activation against pathogens.
- Rad23 facilitates proteasome targeting of ubiquitinated proteins using its UbL and UBA domains.
Purpose of the Study:
- To investigate the role of Rad23 in modulating antigen presentation and CD8+ T-cell responses.
- To explore the potential of Rad23 as a tool to enhance or attenuate cellular immunity.
Main Methods:
- Fusion of Rad23 or its UBA domain to green fluorescent protein (GFP) in mammalian cells.
- Assessment of antigen degradation and CD8+ T-cell responses in BALB/c mice.
- Coexpression of unfused Rad23 with destabilized GFP to study inhibitory effects.
Main Results:
- Fusion of Rad23/UBA to GFP increased proteasomal degradation and enhanced antigen-specific CD8+ T-cell responses.
- Coexpression of unfused Rad23 with GFP inhibited degradation and attenuated T-cell responses.
- Demonstrated Rad23's dual role in controlling proteasomal degradation and T-cell immunity.
Conclusions:
- Rad23 can be engineered to enhance or suppress CD8+ T-cell responses by modulating antigen proteasomal degradation.
- Rad23 holds potential for applications in gene therapy and genetic vaccines requiring tailored immune modulation.